Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alanine racemase is a pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the reversible racemization of L-alanine to D-alanine, a step essential for peptidoglycan biosynthesis in bacteria. D-alanine–D-alanine ligase catalyzes the ATP-dependent ligation of two D-alanine molecules to form the dipeptide D-Ala–D-Ala, which is then incorporated into the bacterial cell wall peptide chain. Both enzymes are absent in higher eukaryotes and are essential for bacterial viability, making them prime targets for antibiotic development, particularly D-cycloserine, which inhibits both. Their inhibition leads to disruption of cell wall synthesis and bacterial lysis.
Inhibition of alanine racemase blocks racemization of L-alanine to D-alanine, depleting D-alanine needed for cell wall synthesis. Inhibition of D-alanine–D-alanine ligase blocks dipeptide formation essential for peptidoglycan crosslinking. D-cycloserine acts by irreversible covalent modification (alanine racemase), and through phosphorylation-based inhibition (D-alanine–D-alanine ligase).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alanine racemase and D-alanine–D-alanine ligase (Alr (for alanine racemase), Ddl (for D-alanine–D-alanine ligase)).